{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T01:50:22Z","timestamp":1794707422026,"version":"4.9.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Knight ADRC Developmental Grant"},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P30 AG066444"],"award-info":[{"award-number":["P30 AG066444"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P30 AG066444"],"award-info":[{"award-number":["P30 AG066444"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P01 AG03991"],"award-info":[{"award-number":["P01 AG03991"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P01 AG026276"],"award-info":[{"award-number":["P01 AG026276"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG070941"],"award-info":[{"award-number":["R01AG070941"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zenith award"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41591-025-03617-7","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T05:58:22Z","timestamp":1743400702000},"page":"2044-2053","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":160,"title":["Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7736-2614","authenticated-orcid":false,"given":"Kanta","family":"Horie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5210-9230","authenticated-orcid":false,"given":"Gemma","family":"Salvad\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama K.","family":"Koppisetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-8378","authenticated-orcid":false,"given":"Shorena","family":"Janelidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas R.","family":"Barth\u00e9lemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2543-4553","authenticated-orcid":false,"given":"Yingxin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7639-8727","authenticated-orcid":false,"given":"Chihiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2109-2955","authenticated-orcid":false,"given":"Brian A.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8114-0552","authenticated-orcid":false,"given":"Tammie L. S.","family":"Benzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stomrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3400-0856","authenticated-orcid":false,"given":"David M.","family":"Holtzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Mattsson-Carlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9267-1930","authenticated-orcid":false,"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1680-1465","authenticated-orcid":false,"given":"Suzanne E.","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-7286","authenticated-orcid":false,"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7729-1702","authenticated-orcid":false,"given":"Randall J.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"key":"3617_CR1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948","author":"CH van Dyck","year":"2022","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2212948 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3617_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"3617_CR3","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X","volume":"45","author":"JL Price","year":"1999","unstructured":"Price, J. L. & Morris, J. C. Tangles and plaques in nondemented aging and \u2018preclinical\u2019 Alzheimer\u2019s disease. Ann. Neurol. 45, 358\u2013368 (1999).","journal-title":"Ann. Neurol."},{"key":"3617_CR4","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","volume":"21","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele, R., van der Kant, R. & Hansson, O. Tau biomarkers in Alzheimer\u2019s disease: towards implementation in clinical practice and trials. Lancet Neurol. 21, 726\u2013734 (2022).","journal-title":"Lancet Neurol."},{"key":"3617_CR5","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","volume":"28","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele, R. et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat. Med. 28, 2381\u20132387 (2022).","journal-title":"Nat. Med."},{"key":"3617_CR6","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1001\/jamaneurol.2018.3692","volume":"76","author":"R Smith","year":"2019","unstructured":"Smith, R., Wibom, M., Pawlik, D., Englund, E. & Hansson, O. Correlation of in vivo [18F]flortaucipir with postmortem Alzheimer disease tau pathology. JAMA Neurol. 76, 310\u2013317 (2019).","journal-title":"JAMA Neurol."},{"key":"3617_CR7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jalz.2019.09.079","volume":"16","author":"VJ Lowe","year":"2020","unstructured":"Lowe, V. J. et al. Tau-positron emission tomography correlates with neuropathology findings. Alzheimers Dement. 16, 561\u2013571 (2020).","journal-title":"Alzheimers Dement."},{"key":"3617_CR8","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson, O. Biomarkers for neurodegenerative diseases. Nat. Med. 27, 954\u2013963 (2021).","journal-title":"Nat. Med."},{"key":"3617_CR9","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1002\/alz.12875","volume":"19","author":"R Smith","year":"2023","unstructured":"Smith, R. et al. Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients. Alzheimer\u2019s Dement. 19, 2497\u20132507 (2023).","journal-title":"Alzheimer\u2019s Dement."},{"key":"3617_CR10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze, S. et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat. Med. 26, 379\u2013386 (2020).","journal-title":"Nat. Med."},{"key":"3617_CR11","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772\u2013781 (2020).","journal-title":"JAMA"},{"key":"3617_CR12","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","volume":"30","author":"NR Barth\u00e9lemy","year":"2024","unstructured":"Barth\u00e9lemy, N. R. et al. Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests. Nat. Med. 30, 1085\u20131095 (2024).","journal-title":"Nat. Med."},{"key":"3617_CR13","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","volume":"3","author":"O Hansson","year":"2023","unstructured":"Hansson, O., Blennow, K., Zetterberg, H. & Dage, J. Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials. Nat. Aging 3, 506\u2013519 (2023).","journal-title":"Nat. Aging"},{"key":"3617_CR14","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault, J. et al. Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography. JAMA Neurol. 80, 188\u2013199 (2023).","journal-title":"JAMA Neurol."},{"key":"3617_CR15","doi-asserted-by":"publisher","first-page":"e2463","DOI":"10.15252\/emmm.202217123","volume":"15","author":"G Salvad\u00f3","year":"2023","unstructured":"Salvad\u00f3, G. et al. Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. EMBO Mol. Med. 15, e2463 (2023).","journal-title":"EMBO Mol. Med."},{"key":"3617_CR16","doi-asserted-by":"publisher","first-page":"fcae081","DOI":"10.1093\/braincomms\/fcae081","volume":"6","author":"KL Meeker","year":"2024","unstructured":"Meeker, K. L. et al. Comparison of cerebrospinal fluid, plasma and neuroimaging biomarker utility in Alzheimer\u2019s disease. Brain Commun. 6, fcae081 (2024).","journal-title":"Brain Commun."},{"key":"3617_CR17","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","volume":"26","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy, N. R. et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease. Nat. Med. 26, 398\u2013407 (2020).","journal-title":"Nat. Med."},{"key":"3617_CR18","doi-asserted-by":"publisher","first-page":"eaaz2387","DOI":"10.1126\/sciadv.aaz2387","volume":"6","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren, N. et al. A\u03b2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer\u2019s disease. Sci. Adv. 6, eaaz2387 (2020).","journal-title":"Sci. Adv."},{"key":"3617_CR19","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","volume":"29","author":"K Horie","year":"2023","unstructured":"Horie, K. et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer\u2019s disease. Nat. Med. 29, 1954\u20131963 (2023).","journal-title":"Nat. Med."},{"key":"3617_CR20","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s43587-023-00380-7","volume":"3","author":"NR Barth\u00e9lemy","year":"2023","unstructured":"Barth\u00e9lemy, N. R. et al. CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer\u2019s disease. Nat. Aging 3, 391\u2013401 (2023).","journal-title":"Nat. Aging"},{"key":"3617_CR21","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","volume":"71","author":"MC Donohue","year":"2014","unstructured":"Donohue, M. C. et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 71, 961\u2013970 (2014).","journal-title":"JAMA Neurol."},{"key":"3617_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein, M. F., Folstein, S. E. & McHugh, P. R. \u2018Mini-mental state\u2019: a practical method for grading the cognitive state of patients for the clinician. J. Psychiatric Res. 12, 189\u2013198 (1975).","journal-title":"J. Psychiatric Res."},{"key":"3617_CR23","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/brain\/awaa373","volume":"144","author":"K Horie","year":"2021","unstructured":"Horie, K., Barth\u00e9lemy, N. R., Sato, C. & Bateman, R. J. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer\u2019s disease. Brain 144, 515\u2013527 (2021).","journal-title":"Brain"},{"key":"3617_CR24","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.76494","volume":"11","author":"S L\u00f6vestam","year":"2022","unstructured":"L\u00f6vestam, S. et al. Assembly of recombinant tau into filaments identical to those of Alzheimer\u2019s disease and chronic traumatic encephalopathy. eLife 11, e76494 (2022).","journal-title":"eLife"},{"key":"3617_CR25","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1073\/pnas.98.3.944","volume":"98","author":"NE Robinson","year":"2001","unstructured":"Robinson, N. E. & Robinson, A. B. Molecular clocks. Proc. Natl Acad. Sci. USA 98, 944\u2013949 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3617_CR26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1468-1331.2008.02069.x","volume":"15","author":"SG Lindquist","year":"2008","unstructured":"Lindquist, S. G. et al. Alzheimer disease-like clinical phenotype in a family with FTDP-17 caused by a MAPT R406W mutation. Eur. J. Neurol. 15, 377\u2013385 (2008).","journal-title":"Eur. J. Neurol."},{"key":"3617_CR27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00401-006-0048-x","volume":"111","author":"R de Silva","year":"2006","unstructured":"de Silva, R. et al. An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies. Acta Neuropathol. 111, 329\u2013340 (2006).","journal-title":"Acta Neuropathol."},{"key":"3617_CR28","doi-asserted-by":"publisher","unstructured":"Qi, C. et al. Tau filaments with the Alzheimer fold in human MAPT mutants V337M and R406W. Nat. Struct. Mol. Biol. https:\/\/doi.org\/10.1038\/s41594-025-01498-5 (2025).","DOI":"10.1038\/s41594-025-01498-5"},{"key":"3617_CR29","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1093\/brain\/aww163","volume":"139","author":"R Smith","year":"2016","unstructured":"Smith, R. et al. 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain 139, 2372\u20132379 (2016).","journal-title":"Brain"},{"key":"3617_CR30","doi-asserted-by":"publisher","first-page":"e1017","DOI":"10.1212\/WNL.0000000000012448","volume":"97","author":"EE Wolters","year":"2021","unstructured":"Wolters, E. E. et al. [18F]Flortaucipir PET across various MAPT mutations in presymptomatic and symptomatic carriers. Neurology 97, e1017\u2013e1030 (2021).","journal-title":"Neurology"},{"key":"3617_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13195-019-0470-7","volume":"11","author":"RM Tsai","year":"2019","unstructured":"Tsai, R. M. et al. 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimer\u2019s Res. Ther. 11, 13 (2019).","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"3617_CR32","doi-asserted-by":"publisher","first-page":"e947","DOI":"10.1212\/WNL.0000000000005117","volume":"90","author":"DT Jones","year":"2018","unstructured":"Jones, D. T. et al. In vivo 18F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. Neurology 90, e947\u2013e954 (2018).","journal-title":"Neurology"},{"key":"3617_CR33","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1093\/brain\/awab392","volume":"145","author":"JP Levy","year":"2021","unstructured":"Levy, J. P. et al. 18F-MK-6240 tau-PET in genetic frontotemporal dementia. Brain 145, 1763\u20131772 (2021).","journal-title":"Brain"},{"key":"3617_CR34","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s00259-022-06065-4","volume":"50","author":"AF Santillo","year":"2023","unstructured":"Santillo, A. F. et al. [18F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes. Eur. J. Nucl. Med. Mol. Imaging 50, 1371\u20131383 (2023).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"3617_CR35","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jama.2024.13855","volume":"332","author":"S Palmqvist","year":"2024","unstructured":"Palmqvist, S. et al. Blood biomarkers to detect Alzheimer disease in primary c775are and secondary care. JAMA 332, 1245\u20131257 (2024).","journal-title":"JAMA"},{"key":"3617_CR36","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack","year":"2016","unstructured":"Jack, C. R. et al. A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87, 539\u2013547 (2016).","journal-title":"Neurology"},{"key":"3617_CR37","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr.","year":"2024","unstructured":"Jack, C. R. Jr. et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimer\u2019s Dement. 20, 5143\u20135169 (2024).","journal-title":"Alzheimer\u2019s Dement."},{"key":"3617_CR38","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/ana.24454","volume":"78","author":"BW Patterson","year":"2015","unstructured":"Patterson, B. W. et al. Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann. Neurol. 78, 439\u2013453 (2015).","journal-title":"Ann. Neurol."},{"key":"3617_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34129-4","volume":"13","author":"A Pichet Binette","year":"2022","unstructured":"Pichet Binette, A. et al. Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer\u2019s disease. Nat. Commun. 13, 6635 (2022).","journal-title":"Nat. Commun."},{"key":"3617_CR40","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/ana.24711","volume":"80","author":"H Cho","year":"2016","unstructured":"Cho, H. et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann. Neurol. 80, 247\u2013258 (2016).","journal-title":"Ann. Neurol."},{"key":"3617_CR41","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1007\/s00259-021-05401-4","volume":"48","author":"A Leuzy","year":"2021","unstructured":"Leuzy, A. et al. A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. Eur. J. Nucl. Med. Mol. Imaging 48, 2295\u20132305 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"3617_CR42","doi-asserted-by":"publisher","first-page":"i","DOI":"10.1037\/h0093567","volume":"60","author":"SG Armitage","year":"1946","unstructured":"Armitage, S. G. An analysis of certain psychological tests used for the evaluation of brain injury. Psychol. Monographs 60, i\u201348 (1946).","journal-title":"Psychol. Monographs"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03617-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03617-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03617-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:10:55Z","timestamp":1776856255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03617-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3617"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03617-7","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]},"assertion":[{"value":"2 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.H. is an Eisai-sponsored voluntary research associate professor at Washington University and has received a salary from Eisai. Washington University, R.J.B. and D.M.H. have equity ownership interest in C2N Diagnostics. R.J.B. and D.M.H. receive income from C2N Diagnostics for serving on the scientific advisory board. K.H., N.R.B., C.S. and R.J.B. may receive income based on technology (Methods to detect MTBR tau isoforms and use thereof; PCT\/US2020\/046224) licensed by Washington University to C2N Diagnostics. K.H., H.J., D.M.H. and R.J.B. may receive income based on technology (Anti-tau MTBR antibodies and methods to detect endogenously cleaved fragments of tau and uses thereof; PCT\/US2023\/072738) licensed by Washington University to C2N Diagnostics. R.J.B. is an unpaid scientific advisory board member of Roche and Biogen, and receives research funding from Avid Radiopharmaceuticals, Janssen, Roche or Genentech, Eli Lilly, Eisai, Biogen, AbbVie, Bristol Myers Squibb and Novartis. O.H. is an employee of Eli Lilly and Lund University and has previously acquired research support (for Lund University) from AVID Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare and Roche. In the past 2\u2009years, he has received consultancy or speaker fees from ALZpath, BioArctic, Biogen, Bristol Meyer Squibb, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. S.E.S. has served on scientific advisory boards or given lectures for Eisai, Eli Lilly and Novo Nordisk. D.M.H. is on the scientific advisory board of Genentech, Denali and Cajal Neurosciences and Switch, and consults for Asteroid and Roche. S.P. has acquired research support (for the institution) from ki elements or ADDF and Avid. In the past 2\u2009years, he has received consultancy or speaker fees from BioArctic, Biogen, Eisai, Lilly, Novo Nordisk and Roche. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}